Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome (ASAPIII)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02067910|
Recruitment Status : Recruiting
First Posted : February 20, 2014
Last Update Posted : May 8, 2018
|Condition or disease||Intervention/treatment||Phase|
|Sjögren's Syndrome||Drug: Abatacept SC||Phase 3|
Background: Primary Sjögren's syndrome (pSS) is a chronic inflammatory and lymphoproliferative disease with autoimmune features. pSS is characterised by a progressive lymphocytic infiltration of the exocrine glands, notably the lacrimal and salivary glands. The main clinical features are a progressive dryness of the eyes, mouth, vagina and skin. Furthermore, various extraglandular manifestations may develop of which restricting fatigue is the most common. Patients may be restricted in their activities and their participation in society, resulting in a reduced health-related quality of life and an impaired socioeconomic status. The latter results in lower employment rates and more disability as compared to the general population. The estimated prevalence of pSS in the general population is between 0.5-2%, which makes pSS, after rheumatoid arthritis (RA), the most common systemic autoimmune disease. Most of the traditional anti-rheumatic drugs used in RA and systemic lupus erythematosus have been tried in pSS with limited results. Currently, biological agents have been introduced in various systemic autoimmune diseases. These biological agents enhance or replace conventional immunosuppressive therapy. In contrast to RA and systemic lupus erythematosus (SLE), no biological agent has yet been approved for the treatment of pSS. Abatacept is a fully human soluble co-stimulation modulator that selectively targets the CD80/CD86:CD28 co-stimulatory signal required for full T-cell activation, and T cell dependent activation of B-cells. We have recently shown in a phase II open label study that Abatacept treatment of pSS patients has promising efficacy results, as reflected by a significant decrease in disease activity indices such as the EULAR Sjögrens Syndrome Disease Activity Index and Patient Reported Index (ESSDAI and ESSPRI) (Meiners et al., 2014). Importantly, we also have shown that Abatacept is safe and side effects are very limited in pSS patients. For these reasons a larger and randomized clinical trial with Abatacept is warranted.
Objective: Primary: to evaluate efficacy of weekly subcutaneous (SC) administration of Abatacept vs placebo on disease activity assessed with ESSDAI at in patients with pSS. Secondary: to assess efficacy of Abatacept on clinical, functional, laboratory, subjective, and histological parameters over 48 weeks in patients with pSS. To evaluate the safety of abatacept, by monitoring serious adverse events (SAE), adverse events (AE) related SAE and AE, treatment discontinuation related to SAE and AE, and lab abnormalities over 48 weeks in patients with pSS. Exploratory: to assess efficacy on laboratory parameters over 48 weeks in patients with pSS.
Study design: The first stage is a 24-week randomized, double-blind, placebo-controlled phase III study to assess the efficacy and safety of Abatacept (weekly SC administration of 125 mg Abatacept or placebo) in patients with pSS. The primary endpoint (ESSDAI) will be evaluated at 24 weeks. The second stage is composed of a 24-week open-label period in which both Abatacept and placebo treated patients will receive Abatacept for 24 weeks. The total study duration will be 48 weeks where after the study will be opened.
Study population: 88 adult pSS patients
Intervention: Weekly subcutaneous administration of 125 mg Abatacept up to 48 weeks.
Main endpoints: The primary endpoint is the difference in ESSDAI score between the Abatacept and the placebo group at 24 weeks. Secondary endpoints are clinical, functional, laboratory, subjective, and histological parameters and the prevalence of adverse events, treatment discontinuation and laboratory abnormalities.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||88 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome (ASAP III Study = Abatacept Sjögren Active Patients Phase III Study)|
|Study Start Date :||August 2014|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||July 2019|
Active Comparator: Abatacept SC
Weekly subcutaneous administration of 125 mg Abatacept during 48 weeks
Drug: Abatacept SC
Weekly subcutaneous administration of 125 mg Abatacept
Placebo Comparator: Placebo
First phase: Weekly subcutaneous administration of placebo during 24 weeks. Second phase: Weekly subcutaneous administration of 125 mg Abatacept during 24 weeks.
Drug: Abatacept SC
Weekly subcutaneous administration of 125 mg Abatacept
- ESSDAI [ Time Frame: 24 weeks ]
- Safety parameters [ Time Frame: Week 4, 8, 12, 24, 28, 32, 36, 48 ]Adverse events will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) v.14.0.
- ESSDAI (at time-points other than 24 weeks) [ Time Frame: Week 0, 4, 8, 12, 28, 32, 36, 48 ]
- DAS28(CRP) and DAS28(ESR) [ Time Frame: Week 0, 4, 8, 12, 24, 28, 32, 36, 48 ]
- Corticosteroid dose (decrease, stable, increase) [ Time Frame: Week 0, 4, 8, 12, 24, 28, 32, 36, 48 ]
- Salivary gland function [ Time Frame: Week 0, 12, 24, 36 and 48 ]Unstimulated and stimulated whole saliva, sialometric and sialochemical analysis of gland-specific saliva
- Tear gland function [ Time Frame: Week 0, 12, 24, 36 and 48 ]Schirmer test, tear-break-up time, ocular staining score, tears collection, determination of auto-antibodies and cytokines, conjunctival impression cytology
- ESSPRI [ Time Frame: 0, 4, 8, 12, 24, 28, 32, 36, and 48. ]
- Patient and Physician Global assessment of disease activity (patGDA, phyGDA) [ Time Frame: 0, 4, 8, 12, 24, 28, 32, 36, and 48 ]
- Multidimensional Fatigue Index (MFI) [ Time Frame: week 0, 12, 24, 36, and 48 ]
- Health related quality of life (Short Form-36; SF-36) [ Time Frame: week 0, 12, 24, 36, and 48 ]
- Patient Acceptable Symptom State (PASS) [ Time Frame: week 0, 12, 24, 36, and 48 ]
- Female Sexual Function Index (FSFI) [ Time Frame: week 0, 24 and 48 ]
- NRS score vaginal dryness [ Time Frame: Week 0, 24 and 48 ]
- Histological change in parotid gland [ Time Frame: Week 24 ]Follow-up parotid gland biopsy in patients of who a recent (<6 months prior to inclusion) parotid gland biopsy is available.
- Laboratory immune markers [ Time Frame: Week 0, 4, 8, 12, 24, 28, 32, 36 and 48 ]Serum levels of ANA and IgM-Rf, Serum levels of anti-SSA, anti-SSB, Immunoglobulins (IgG, IgA, IgM), T and B cell subsets, Cytokines, Free light chain, MxA, β2 microglobulin, Complement (C3 and C4), CRP, ESR
- EQ-5D [ Time Frame: Week 0, 12, 24, 36, 48 ]
- Work Participation and Activity Impairment questionnaire (WPAI) [ Time Frame: Week 0, 12, 24, 36 and 48 ]
- Ultrasound of salivary glands [ Time Frame: Week 0, 24 and 48 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02067910
|Contact: H. Bootsma, MD, PhD||+3150-3613432||H.Bootsma@umcg.nl|
|Contact: J.F. van Nimwegen, MD||+31655256017||J.email@example.com|
|University Medical Center Groningen||Recruiting|
|Groningen, Netherlands, 9700RB|
|Principal Investigator: H. Bootsma, MD, PhD|
|Principal Investigator:||H. Bootsma, MD, PhD||University Medical Center Groningen|